NM8074 for adults with C3 glomerulopathy kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This early-phase study tests whether NM8074 can help adults with C3 glomerulopathy. It focuses on people with low blood C3 levels and protein in the urine, and it includes close monitoring and required vaccinations to reduce infection risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old when you agree to join
- You must have C3 glomerulopathy confirmed by a kidney biopsy within the past 12 months
- Your screening blood test must show low C3 levels, and you must have protein in your urine
- Your kidney filtration (eGFR) must be at least 20 and no more than 60
- You must agree to vaccinations (meningitis, pneumonia, and flu-related bacteria) or have proof you already had them
- You must use birth control if you can become pregnant (and have a negative pregnancy test); men must use contraception and not donate sperm
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called OMS906 for people with C3G or ICGN (immune-related kidney diseases). It aims to see if the drug is safe and can reduce kidney damage. You may qualify if you have a confirmed diagnosis, high protein in your urine, and stable kidney function.
This study tests an experimental drug called SGB-9768 for people with certain kidney diseases that involve complement protein deposits. The goal is to see if it can reduce kidney damage and protein loss in urine.
This trial tests an experimental medicine called NM8074 for people with IgA nephropathy, a type of kidney disease. It aims to see if NM8074 can help protect your kidneys and reduce damage.
This Phase 2 study tests how well and how safely NM8074 works for adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not recently received a similar “complement inhibitor” medicine. It may help reduce PNH-related blood cell breakdown and anemia, and it will closely monitor side effects.
This Phase 2 study tests NM8074, a medicine that targets the immune system’s complement pathway, to treat atypical HUS (aHUS) that is coming back or not responding well. It may help stop ongoing blood vessel damage and improve blood counts and kidney function.
This trial tests a new drug called CPV-104. First, healthy volunteers will receive a single dose to check safety. Then, people with C3 glomerulopathy (a rare kidney disease) will receive multiple doses to see if it helps and is safe.
Hear when a new C3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.